AstraZeneca PLC (AZN)

NYSE: AZN · USD

$169

-0.66 (-0.4%)· Recorded snapshot

Market cap	262.5B
Revenue (ttm)	61.4B
Net income (ttm)	10.4B
EPS (ttm)	$6.70
Shares out	1.6B
P/E (trailing)	25.3x
P/E (forward)	15.8x
Dividend	$3.23 (1.91%)
Volume	1,433,288
Beta	0.21

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 61.4B
Net income (ttm): 10.4B
EPS (ttm): $6.70
P/E (trailing): 25.3x
P/E (forward): 15.8x
Market cap: 262.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Manter

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E15.8

P25 n/aP50 n/aP75 n/a

Trailing P/E25.3

P25 n/aP50 n/aP75 n/a

ROE22

P25 n/aP50 n/aP75 n/a

ROIC16.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AZN indicators

Market & fundamental data

Available fields

287

Groups with data

Currency

USD

Showing 287 of 287 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000901832
Company name	AstraZeneca PLC
Country	United Kingdom
Country code	US
CUSIP number	G0593M107
Earnings date	2026-10-30
Earnings time	bmo
Employees	95,100
Employees change	2,200
Employees growth	2.37%
Enterprise value	$290B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1992
Industry	Drug Manufacturers - General
IPO date	1993-05-12
Is primary listing	No
Is SPAC	No
ISIN number	GB0009895292
Last 10-K release date	2026-02-24
Last earnings date	2026-07-27
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$262.5B
Market cap category	Mega-Cap
Next earnings date	2026-10-30
Options	Yes
Price	$169.42
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	AZN
Tags	weight-loss, pharmaceuticals
Website	https://www.astrazeneca.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	17.45x
Average P/E ratio (10Y)	84.65x
Average P/E ratio (3Y)	30.99x
Average P/E ratio (5Y)	130.79x
Earnings yield	3.96%
EV/Earnings	27.86x
EV/EBIT	19.43x
EV/EBITDA	14.37x
EV/FCF	27.28x
EV/Sales	4.74x
FCF / EV yield	3.67%
FCF yield	4.05%
Forward EV/Sales	4.48x
Forward P/E	15.85x
Forward P/S	4.06x
Graham number	70.31467
Graham upside	-58.71%
Industry forward P/E	18.51x
Industry P/E	35.9x
Lynch fair value	$152.58
Lynch upside	-10.41%
P/(FCF - SBC) ratio	25.58x
P/(OCF - SBC) ratio	19.76x
P/B ratio	5.23x
P/E ratio	25.27x
P/FCF ratio	24.7x
P/OCF ratio	19.24x
P/S ratio	4.29x
Price/EBITDA ratio	13.01x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	24.42%
EBITDA margin	33%
Effective tax rate	16.95%
FCF margin	17.38%
Gross margin	81.69%
Operating margin	24.42%
Pretax margin	20.51%
Profit margin	17.02%
Profit per employee	$109,842
Profitable quarters	18
Profitable years	24
Revenue per employee	$645,279
ROA	8.21%
ROA (5Y)	5.95%
ROCE	17.78%
ROE	21.96%
ROE (5Y)	13.03%
ROIC	16.43%
ROIC (5Y)	13.29%
SBC / revenue	0.6%
Tax / revenue	3.48%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	25.84%
EPS growth (Q)	2.55%
EPS growth (QoQ)	-18.27%
EPS growth 10Y	14.33%
EPS growth 3Y	19.13%
EPS growth 5Y	18.4%
EPS growth quarters	11
EPS growth years	4
FCF growth	-4.55%
FCF growth (Q)	-22.92%
FCF growth (QoQ)	-25.25%
FCF growth 3Y	5.66%
FCF growth 5Y	14.81%
Gross profit growth	7.69%
Gross profit growth (Q)	7.25%
Gross profit growth 3Y	9.19%
Gross profit growth 5Y	17.24%
Net income growth	25.93%
Net income growth (Q)	2.33%
Net income growth (QoQ)	-18.6%
Net income growth 3Y	19.23%
Net income growth 5Y	22.6%
Net income growth quarters	11
Net income growth years	4
OCF growth	2.32%
OCF growth (Q)	-15.39%
OCF growth (QoQ)	-14.71%
OCF growth 10Y	14.02%
OCF growth 3Y	10.41%
OCF growth 5Y	16.27%
Operating income growth	5.8%
Operating income growth (Q)	2.88%
Operating income growth 3Y	9.95%
Operating income growth 5Y	31.31%
Revenue growth	8.61%
Revenue growth (Q)	6.41%
Revenue growth (QoQ)	0.63%
Revenue growth 10Y	9.81%
Revenue growth 3Y	11.32%
Revenue growth 5Y	15.75%
Revenue growth quarters	13
Revenue growth years	7

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-3B
Depreciation and amortization	$5.3B
EBIT	$15B
EBITDA	$20.2B
EPS	$6.70
FCF per share	$6.88
Financing cash flow	$-7.7B
Free cash flow	$10.7B
Free cash flow minus SBC	$10.3B
Gross profit	$50.1B
Income taxes	$2.1B
Investing cash flow	$-8.2B
Net borrowing	$-1.9B
Net cash flow	$-2.1B
Net income	$10.4B
Operating cash flow minus SBC	$13.3B
Operating income	$15B
Revenue	$61.4B
Stock-based compensation	$366M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.58
Book value per share	$32.43
Debt / EBITDA	1.57
Debt / equity	0.64
Debt / FCF	3.03
Goodwill	$21.2B
Interest coverage	10.64
Long-term assets	$87.9B
Long-term liabilities	$33.9B
Net cash (debt)	$-27.4B
Net cash / market cap	-10.39%
Net debt / EBITDA	1.35
Net debt / equity	0.54
Net debt / FCF	2.57
Piotroski F-Score	7
Property, plant and equipment	$16.3B
Shareholders' equity	$50.4B
Tangible book value	$-8.6B
Tangible book value per share	$-5.55
Total assets	$115.8B
Total cash	$5B
Total debt	$32.4B
Total liabilities	$65.5B
WACC	5.22%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.54
Current assets	$28B
Current liabilities	$31.6B
Current ratio	0.89
Inventory turnover	1.68
Net working capital	$-2.2B
Quick ratio	0.66
Working capital	$-3.6B
Working capital turnover	-14.99

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.03%
Dividend growth	3.19%
Dividend growth (10Y)	5.45%
Dividend growth (3Y)	47.82%
Dividend growth (5Y)	2.9%
Dividend growth years	1
Dividend payment date	2026-09-08
Dividend payment years	3
Dividend payout frequency	Semi-Annual
Dividend per share	$3.23
Dividend yield	1.91%
Ex-dividend date	2026-08-07
FCF payout ratio	46.96%
Last dividend	$1.06
Payout ratio	48.18%
Shareholder yield	1.93%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	199.05%
10Y return CAGR	13.47%
10Y total return	253.68%
150-day SMA	$175.76
15Y price change	249.66%
15Y return CAGR	11.12%
15Y total return	385.95%
1D price change	-0.39%
1M price change	1.7%
1M total return	1.7%
1W price change	0.35%
1W total return	0.35%
1Y price change	3.31%
1Y return CAGR	5.09%
1Y total return	5.08%
20-day SMA	$163.65
200-day SMA	$180.13
20Y price change	173.02%
20Y return CAGR	7.39%
20Y total return	316.25%
3M price change	-0.14%
3M total return	0.53%
3Y price change	39.49%
3Y return CAGR	13.41%
3Y total return	45.9%
50-day SMA	$163.84
50-day SMA vs 200-day SMA	50under200
52-week high	$212.71
52-week high date	2026-02-18
52-week low	$153.41
52-week low date	2026-08-03
5Y price change	37.95%
5Y return CAGR	7.61%
5Y total return	44.28%
6M price change	-9.65%
6M total return	-9.05%
All-time high	$212.71
All-time high date	2026-02-18
All-time low	$30.20
All-time low date	2009-03-05
Average true range (ATR)	$3.54
Average volume	2.8M
Beta (5Y)	0.21
Change from 52-week high	-20.35%
Change from 52-week low	10.43%
Change from all-time high	-20.36%
Change from all-time low	460.96%
Change from open	0.45%
Day's gap	-0.83%
Dollar volume	$242.8M
High price	$171.70
Low price	$168.00
Monthly RSI	51.93
Open price	$168.66
Position in 52-week range	38.38%
Premarket change	-0.71%
Premarket close	$170.08
Premarket price	$168.88
Premarket volume	29.7K
Previous close	$170.08
Price vs 150-day SMA	-3.61%
Price vs 20-day SMA	3.52%
Price vs 200-day SMA	-5.95%
Price vs 50-day SMA	3.4%
Relative volume	0.51
RSI	57.6
Sharpe ratio	0.1
Sharpe ratio (3Y)	0.27
Sharpe ratio (5Y)	0.31
Sortino ratio	0.34
Sortino ratio (3Y)	0.55
Sortino ratio (5Y)	0.61
Volume	1.4M
Weekly RSI	49.16
YTD price change	-3.47%
YTD total return	-1.81%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.5B
Float percentage	99.5%
Shares change (QoQ)	-0.06%
Shares change (YoY)	-0.03%
Shares held by insiders	0.04%
Shares held by institutions	74.28%
Shares outstanding	1.6B
Short % of float	0.17%
Short % of shares	0.17%
Short ratio	0.9 days

Deeper analysis on AZN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AZN report

Is a complete AZN research report available?

No complete published report is available for AstraZeneca PLC (AZN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

AstraZeneca PLC (AZN)

Price

Financial snapshot

Fair-value bridge

Latest news · AZN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AZN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AZN

Frequently asked questions